Australia has cleared ATG-201, Antengene Corporation Limited's (HKEX: 6996.HK) CD19 × CD3 bispecific T-cell engager (TCE), to enter first-in-human testing, with the country's Human Research Ethics Committee (HREC) approving the Phase I ATTRACT study and the Therapeutic Goods Administration (TGA) completing its Clinical Trial Notification process. The approval follows China's NMPA IND clearance in June 2026, opening a two-jurisdiction first-in-human program for the molecule.
ATG-201 is built on Antengene's proprietary AnTenGager platform, which uses a "2+1" format — two CD19-binding arms and one CD3-binding arm — combined with steric hindrance masking technology that restricts T-cell activation to the presence of CD19-expressing target cells. The design is intended to deplete pathogenic B cells while reducing cytokine release syndrome (CRS), a known toxicity that has constrained earlier CD19/CD3 bispecific approaches.
The ATTRACT study is a dose-escalation and dose-expansion Phase I trial evaluating ATG-201 monotherapy in adult patients with B cell-related autoimmune diseases. Primary endpoints are safety, tolerability, and determination of the recommended Phase II dose (RP2D); secondary endpoints include pharmacokinetic and pharmacodynamic profiling, immunogenicity, and preliminary efficacy. Antengene will conduct the first-in-human studies in both China and Australia before transferring further clinical development to UCB, which holds worldwide exclusive rights to develop, manufacture, and commercialize ATG-201 under a deal signed in March 2026.
The UCB agreement provided Antengene with USD 60 million upfront — confirmed received in July 2026 — plus up to USD 20 million in near-term milestones and eligibility for more than USD 1.1 billion in success-based payments and tiered royalties.